Evome Medical (fka Salona Global) changes name, reports Q3 revenue up 18.5% QoQ and positive Adj. EBITDA

EVOME MEDICAL TECHNOLOGIES INC.

Company renamed Evome Medical Technologies Inc., ticker EVMT effective Jan 22, 2024.
Director Leslie Cross resigned effective Jan 17, 2024; no disagreement disclosed.
Q3 FY2023 (Sep 30): revenue +18.5% QoQ, gross profit +29% QoQ, positive Adj. EBITDA of $749,425.
Reduced Biodex acquisition debt by $428,237 in Q3; balance extended to July 2025.
Plans to launch two new Biodex products (SpaceTek Knee, Reactive Step Trainer) into private PT market.

item 5.02 item 5.03 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Leslie Cross

Director

EVOME MEDICAL TECHNOLOGIES INC.

Effective: 2024-01-17
Filed: January 23, 2024, 6:59 PM ET

On January 17, 2024, Leslie Cross notified the Board of Directors of Salona Global Medical Device Corporation (the "Company") of his intention to resign from the Company's Board of Directors effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Leslie Cross resigned as Director at EVOME MEDICAL TECHNOLOGIES INC..

Action: resigned
Role: Director

Exact text from the filing

On January 17, 2024, Leslie Cross notified the Board of Directors of Salona Global Medical Device Corporation (the "Company") of his intention to resign from the Company's Board of Directors effective immediately.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

EVOME MEDICAL TECHNOLOGIES INC.: Articles amended to reflect corporate name change to Evome Medical Technologies Inc (effective 2024-01-22).

Change: charter amendment
Effective: 2024-01-22

Exact text from the filing

the Board of Directors amended the Company's Articles to reflect the corporate name Evome Medical Technologies Inc.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001062993-24-001181

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.